Literature DB >> 29484498

Bendamustine and G-CSF support.

Osamu Imataki1, Shumpei Uchida2, Shigeyuki Yokokura2, Makiko Uemura2, Norimitsu Kadowaki2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29484498     DOI： 10.1007/s00520-018-4118-0

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


× No keyword cloud information.
  4 in total

1.  Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings.

Authors:  Myron S Czuczman; A Goy; D Lamonica; D A Graf; M C Munteanu; R H van der Jagt
Journal:  Ann Hematol       Date:  2015-09-28       Impact factor: 3.673

2.  Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP.

Authors:  A Bosly; D Bron; A Van Hoof; R De Bock; Z Berneman; A Ferrant; L Kaufman; M Dauwe; G Verhoef
Journal:  Ann Hematol       Date:  2007-10-20       Impact factor: 3.673

3.  Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.

Authors:  K Sue Robinson; Michael E Williams; Richard H van der Jagt; Philip Cohen; Jordan A Herst; Anil Tulpule; Lee S Schwartzberg; Bernard Lemieux; Bruce D Cheson
Journal:  J Clin Oncol       Date:  2008-07-14       Impact factor: 44.544

4.  Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience.

Authors:  Claudio Cerchione; Amalia De Renzo; Maria Di Perna; Roberta Della Pepa; Novella Pugliese; Lucio Catalano; Fabrizio Pane; Marco Picardi
Journal:  Support Care Cancer       Date:  2016-11-03       Impact factor: 3.603
  4 in total
  1 in total

1.  Pegfilgrastim in primary prophylaxis of febrile neutropenia in elderly patients with hematological malignancies-bendamustine and G-CSF support.

Authors:  Claudio Cerchione; Amalia De Renzo; Davide Nappi; Maria Di Perna; Roberta Della Pepa; Novella Pugliese; Lucio Catalano; Fabrizio Pane; Marco Picardi
Journal:  Support Care Cancer       Date:  2019-01-23       Impact factor: 3.603
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.